Title: Treatment of GI dysmotility in scleroderma with the new enterokinetic agent prucalopride
Authors: Boeckxstaens, Guy ×
Bartelsman, JFWM
Lauwers, L
Tytgat, GNJ #
Issue Date: Jan-2002
Publisher: Elsevier science inc
Series Title: American journal of gastroenterology vol:97 issue:1 pages:194-197
Abstract: Scleroderma is a multisystem disorder frequently resulting in disturbed GI motility. Although, especially early in the disease, symptomatic improvement is achieved with prokinetic agents, more severe GI manifestations of scleroderma may be difficult to treat, leading to parenteral feeding and hospitalization. Recently, a new serotonin (5-HT4) receptor agonist prucalopride was shown to have remarkable prokinetic properties, resulting in symptomatic improvement and increased frequency of defecation in patients with chronic functional constipation. Here we report two cases of scleroderma with GI manifestation in which previous prokinetic treatment failed, but where the patients were successfully treated with prucalopride. Our data suggest that prucalopride may be a promising and effective drug to treat GI motility disorders in scleroderma. However, further placebo-controlled double blind studies are needed for full documentation of the usefulness of prucalopride in patients with scleroderma. (C) 2002 by Am. Coll. of Gastroenterology.
ISSN: 0002-9270
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Translational Research in GastroIntestinal Disorders
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science